(ALXN) Alexion Pharmaceuticals – Bull of the Day

Alexion Pharmaceuticals’ (ALXN) third quarter 2011 adjusted earnings of $0.32 per share breezed past the Zacks Consensus Estimate by $0.09 and the year-ago adjusted earnings by $0.11. Results were driven by increased revenues thanks to a strong performance by Soliris, Alexion’s sole marketed product. Following strong third quarter results, Alexion upped its guidance for 2011.

Our estimate is within the revised guidance range provided by the company. We are also impressed by the successful label expansion of Soliris into the aHUS indication in the US and the positive recommendation in the EU. The string of good news has boosted the stock.

We expect the stock to continue performing well and believe that the current price represents an attractive entry point for long-term investors. Our target price is $82.00.

ALEXION PHARMA (ALXN): Free Stock Analysis Report

Zacks Investment Research

About vitalstocks

This is a sample profile field. Vitalstocks is the operating company for Stockbloghub. This will place the picture of the author or company in the profile. Here is another extra line of information.


Powered by Facebook Comments

Similar Posts: | | Drug Manufacturers - Other | Healthcare

RSS feeds: Alexion Pharmaceuticals Inc | ALXN | Drug Manufacturers - Other | Healthcare |

Other Posts by | RSS Feed for this author